Oculis Holding AG OCS
NASDAQ OCS
$12.17 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Oculis Holding AG (OCS) Income towards Parent Company (2022 - 2026)

Oculis Holding AG (OCS) posted quarterly Income towards Parent Company of -$37.1 million for Q1 2026, little changed year-over-year from -$37.3 million in Q1 2025, and down 151.01% quarter-over-quarter from $72.7 million in Q4 2025.

Analysis

Oculis Holding AG (OCS) Income towards Parent Company (2022 - 2026) Analysis & Trends

Oculis Holding AG's Income towards Parent Company history runs 5 years deep, the most recent figure standing at -$37.1 million for Q1 2026.

  • In Q1 2026, Income towards Parent Company changed 0.46% year-over-year to -$37.1 million; the TTM figure through Mar 2026 stood at -$21.0 billion (up 9.94% YoY), while the FY2025 annual figure was -$119.8 million, down 22.42% from the prior year.
  • Income towards Parent Company for Q1 2026 stood at -$37.1 million, down from $72.7 million in the prior quarter.
  • The five-year high for Income towards Parent Company was $72.7 million in Q4 2025, with the low at -$23.3 billion in Q3 2024.
  • The 5-year median for Income towards Parent Company is -$21.5 million (2023), against an average of -$2.8 billion.
  • The sharpest annual moves came in 2024 and 2025: Income towards Parent Company sank 116344.35% in 2024, then jumped 318.67% in 2025.
  • Oculis Holding AG's Income towards Parent Company stood at -$9.6 million in 2022, then tumbled by 47.68% to -$14.1 million in 2023, then plunged by 135.51% to -$33.3 million in 2024, then surged by 318.67% to $72.7 million in 2025, then tumbled by 151.01% to -$37.1 million in 2026.
  • Business Quant data shows OCS's Income towards Parent Company at -$37.1 million in Q1 2026, $72.7 million in Q4 2025, and -$21.0 billion in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Oculis Holding AG 634.75 Mn 345.87 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -202.44
Mar 31, 2026 -625.73
Dec 31, 2025 -525.49
Sep 30, 2025 -400.04
Jun 30, 2025 -591.87
Mar 31, 2025 -767.45
Dec 31, 2024 -764.82
Sep 30, 2024 -554.02
Jun 30, 2024 -563.95
Mar 31, 2024 -504.10
Dec 31, 2023 -383.30
Sep 30, 2023 -543.43
Jun 30, 2023 -422.63
Mar 31, 2023 -3,859.75
Dec 31, 2022 -2,709.24
Sep 30, 2022 -2,982.12
Jun 30, 2022 -3,779.39